Clinical severity in Parkinson’s disease is determined by decline in cortical compensation - Johansson, Martin E.; Toni, Ivan; Kessels, Roy P.C.; Bloem, Bastiaan R.; Helmich, Rick C. (medRxiv, 2023)
Dopaminergic dysfunction in the basal ganglia, particularly in the post-commissural putamen, is often viewed as the primary pathological mechanism behind motor slowing (i.e., bradykinesia) in Parkinson’s disease. However, striatal dopamine loss fails to account for inter-individual differences in motor phenotype and rate of decline, implying that the expression of motor symptoms depends on additional mechanisms, some of which may be compensatory in nature. Building on observations of increased motor-related activity in the parieto-premotor cortex of Parkinson patients, we tested the hypothesis that inter-individual differences in clinical severity are determined by compensatory cortical mechanisms, and not just by basal ganglia dysfunction.Using functional MRI, we measured variability in motor- and selection-related brain activity during a visuomotor task in 353 patients with Parkinson’s disease (≤5 years disease duration) and 60 healthy controls. In this task, we manipulated action selection demand by varying the number of possible actions that individuals could choose from. Clinical variability was characterized in two ways. First, patients were categorized into three previously validated, discrete clinical subtypes: diffuse-malignant (n=42), intermediate (n=128), or mild motor-predominant (n=150). Second, we used the total bradykinesia score across the entire sample as a continuous measure.Patients showed motor slowing (longer response times) and reduced motor-related activity in the basal ganglia compared to controls. However, basal ganglia activity did not differ between clinical subtypes and was not associated with clinical bradykinesia scores. This indicates a limited role for striatal dysfunction in shaping inter-individual differences in symptom severity. Consistent with our hypothesis, we observed enhanced action selection-related activity in the parieto-premotor cortex of patients with a mild-motor predominant subtype, both compared to patients with a diffuse-malignant subtype and to controls. Furthermore, parieto-premotor activity was inversely related to bradykinesia, which points to a compensatory role.We conclude that parieto-premotor compensation, rather than basal ganglia dysfunction, shapes inter-individual variability in symptom severity in Parkinson’s disease. Future interventions may focus on maintaining and enhancing compensatory cortical mechanisms, rather than only attempting to normalize basal ganglia dysfunction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by The Michael J. Fox Foundation for Parkinson’s Research (grant ID #15581). The Personalized Parkinson Project was co-funded by Verily Life Sciences LLC, the city of Nijmegen and the Province of Gelderland, Radboud University Medical Center, and Radboud University. Allowance made available by Health ∼ Holland, Top Sector Life Sciences and Health, to stimulate public-private partnerships. The Centre of Expertise for Parkinson & Movement Disorders was supported by a centre of excellence grant of the Parkinson’s Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical ethical committee METC Oost-Nederland, formerly CMO Arnhem-Nijmegen, gave ethical approval for this work (#2016-2934 and #2018-4785).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon request only, to ensure the privacy of the participants. A data acquisition request can be sent to the corresponding author. All analysis code used in the present study is freely available at https://github.com/mejoh/Personalized-Parkinson-Project-Motor.MDS-UPDRSMovement Disorders Society Unified Parkinson Disease Rating Scale